Publications by authors named "Mark Chiu"

Claim this Profile
E
Engineering tandem VHHs to target different epitopes to enhance antibody-dependent cell-mediated cytotoxicity.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L Chiu

FEBS Open Bio· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases.
Mingcan Yu, Peng Chen, Ying Jin, Sheng Huang, Hao Jiang, Mark L Chiu

Cells· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Hyaluronan Degradation Enhanced Tumor Growth Inhibition in Gastrointestinal Cancer Models.
Fulai Zhou, Guangmao Mu, Honglei Bi, Limin Chen, Zhengxia Zha, Mark L Chiu

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines in the Preparation of Fully Synthetic, Human Single-Domain Antibody Phage Display Libraries.
Mark A Tornetta, Brian P Whitaker, Olivia M Cantwell, Peter N Haytko, Eileen D Pisors, Mark L Chiu

Antibodies (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs.
Nicole A Wilski, Peter Haytko, Zhengxia Zha, Simin Wu, Ying Jin, Mark L Chiu

Pharmaceutics· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models.
Ying Jin, Peng Chen, Huajun Zhou, Guangmao Mu, Simin Wu, Mark L Chiu

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models.
Ying Jin, Ping Sun, Peng Chen, Yuqiang Xu, Guangmao Mu, Mark L Chiu

Front Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases.
Minseon Cho, Susan H Tam, Lihua Shi, Isa Fung, Mark Tornetta, Mark L Chiu

Clin Exp Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases.
Lihua Shi, Mingcan Yu, Ying Jin, Peng Chen, Guangmao Mu, Mark L Chiu

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The process using a synthetic library that generates multiple diverse human single domain antibodies.
Mark A Tornetta, Brian P Whitaker, Olivia M Cantwell, Eileen D Pisors, Lu Han, Mark L Chiu

Antib Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Safety and Pharmacokinetics Study of TAVO101, an Anti-Human Thymic Stromal Lymphopoietin Antibody for the Treatment of Allergic Inflammatory Conditions.
Chao Han, Isa Fung, Di Zhang, Ying Jin, Peng Chen, Mark L Chiu

J Clin Pharmacol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function.
Fulai Zhou, Yinyin Ben, Hao Jiang, Siwen Tan, Guangmao Mu, Mark L Chiu

Biochemistry· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large scale controlled Fab exchange GMP process to prepare bispecific antibodies.
Xia Yao, Mingquan Xie, Yinyin Ben, Yixiang Zhu, Gaoqiang Yang, Mark L Chiu

Front Bioeng Biotechnol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction to the Use of Linear and Nonlinear Regression Analysis in Quantitative Biological Assays.
Stephen W Jarantow, Eileen D Pisors, Mark L Chiu

Curr Protoc· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GFR Estimation in Potential Living Kidney Donors: Race- and Nonrace-based Equations and Measured GFR.
David Alex Goodson, Megan Rose Chalupsky, Nasim Wiegley, Yihung Huang, Mark Chiu

Kidney Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3.
Adam Zwolak, Szeman Ruby Chan, Paul Harvilla, Sally Mahady, Anthony A Armstrong, Mark Chiu

Sci Rep· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
Joost Neijssen, Rosa M F Cardoso, Kristen M Chevalier, Luus Wiegman, Thomas Valerius, Mark L Chiu

J Biol Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
Dennis R Goulet, Adam Zwolak, James A Williams, Mark L Chiu, William M Atkins

Proteins· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of the bispecific antibody IgG subclass on T cell redirection.
Stephanie Kapelski, Erna Cleiren, Ricardo M Attar, Ulrike Philippar, Julien Häsler, Mark L Chiu

MAbs· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody Structure and Function: The Basis for Engineering Therapeutics.
Mark L Chiu, Dennis R Goulet, Alexey Teplyakov, Gary L Gilliland

Antibodies (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a Novel Bispecific Antibody That Activates T Cells and Slows Tumor Growth .
Olesya Chornoguz, Catherine N Leettola, Karen Leander, Kerry Brosnan, Eva Emmell, Mark L Chiu

Monoclon Antib Immunodiagn Immunother· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance.
Dennis R Goulet, Michael J Watson, Susan H Tam, Adam Zwolak, Mark L Chiu

Drug Metab Dispos· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors.
Mehabaw G Derebe, Rupesh K Nanjunda, Gary L Gilliland, Eilyn R Lacy, Mark L Chiu

Immunol Lett· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
Di Zhang, Brian Whitaker, Mehabaw G Derebe, Mark L Chiu

MAbs· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody.
Simon A Hinke, Anne M Cieniewicz, Thomas Kirchner, Katharine D'Aquino, Rupesh Nanjunda, Mark L Chiu

Mol Metab· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis